Literature DB >> 29309308

Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms.

Yu-Chien Kao1, Uta Flucke2, Astrid Eijkelenboom2, Lei Zhang3, Yun-Shao Sung3, Albert J H Suurmeijer4, Cristina R Antonescu3.   

Abstract

Benign/low-grade fibroblastic tumors encompass a broad spectrum of tumors with different morphologies and molecular genetic abnormalities. However, despite significant progress in recent genomic characterization, there are still tumors in this histologic spectrum that are difficult to classify, lacking known molecular characteristics. Triggered by a challenging congenital spindle cell neoplasm arising in the heel of a 1-year-old boy, we applied RNA sequencing for genetic discovery and identified a novel EWSR1-SMAD3 gene fusion. On the basis of the index case superficial acral location and fibroblastic appearance with a nonspecific immunophenotype, we searched our files for similar cases and screened them by fluorescence in situ hybridization for these abnormalities. Thus an identical EWSR1-SMAD3 fusion was identified in 2 additional spindle cell tumors with similar clinicopathologic features. Both cases occurred in the feet of adult women (58 and 61 y old) and were characterized by distinctive nodular growth with zonation pattern of peripheral hypercellular areas arranged in short fascicles, transitioning to hypocellular central areas of hyalinization and infarction. Focal stippled calcification in the collagenous area was present in 1 case. All 3 tumors had similar immunoprofiles, being negative for SMA, CD34, CD31, and S100, but showing consistent ERG positivity of uncertain significance. Follow-up information was available in 2 patients who developed local recurrences after incomplete initial excisions, at 5 and 14 months, respectively. None developed metastatic disease. In summary, we report a group of locally recurrent superficial acral tumors, characterized by bland spindle cell fascicular growth, occasional zonation pattern, ERG positivity, and recurrent EWSR1-SMAD3 gene fusions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29309308      PMCID: PMC5844807          DOI: 10.1097/PAS.0000000000001002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  21 in total

Review 1.  The Smads.

Authors:  C S Hill
Journal:  Int J Biochem Cell Biol       Date:  1999-11       Impact factor: 5.085

Review 2.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis.

Authors:  John Varga
Journal:  Arthritis Rheum       Date:  2002-07

3.  EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy.

Authors:  Jason Y Park; Cynthia Cohen; Dania Lopez; Erica Ramos; Jennifer Wagenfuehr; Dinesh Rakheja
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

4.  Ets Related Gene and Smad3 Proteins Collaborate to Activate Transforming Growth Factor-Beta Mediated Signaling Pathway in ETS Related Gene-Positive Prostate Cancer Cells.

Authors:  Jinbo Fang; Huali Xu; Chunshu Yang; Sharif Morsalin; Shubhalaxmi Kayarthodi; Kunchala Rungsrisuriyachai; Ujwala Gunnal; Brittany Mckenzie; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-09-01

5.  Regulators and mediators of radiation-induced fibrosis: Gene expression profiles and a rationale for Smad3 inhibition.

Authors:  Judy W Lee; Richard A Zoumalan; Cristian D Valenzuela; Phuong D Nguyen; John P Tutela; Benjamin R Roman; Stephen M Warren; Pierre B Saadeh
Journal:  Otolaryngol Head Neck Surg       Date:  2010-10       Impact factor: 3.497

6.  FN1-EGF gene fusions are recurrent in calcifying aponeurotic fibroma.

Authors:  Florian Puls; Jakob Hofvander; Linda Magnusson; Jenny Nilsson; Elaine Haywood; Vaiyapuri P Sumathi; D Chas Mangham; Lars-Gunnar Kindblom; Fredrik Mertens
Journal:  J Pathol       Date:  2016-03       Impact factor: 7.996

7.  Recurrent Somatic PDGFRB Mutations in Sporadic Infantile/Solitary Adult Myofibromas But Not in Angioleiomyomas and Myopericytomas.

Authors:  Abbas Agaimy; Matthias Bieg; Michael Michal; Helene Geddert; Bruno Märkl; Jan Seitz; Evgeny A Moskalev; Matthias Schlesner; Markus Metzler; Arndt Hartmann; Stefan Wiemann; Michal Michal; Thomas Mentzel; Florian Haller
Journal:  Am J Surg Pathol       Date:  2017-02       Impact factor: 6.394

8.  ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Yuichi Takashi; Nobuaki Ito; Seiji Fukumoto; Masashi Fukuyama
Journal:  Med Mol Morphol       Date:  2015-06-30       Impact factor: 2.309

9.  ERG expression in chondrogenic bone and soft tissue tumours.

Authors:  Wonwoo Shon; Andrew L Folpe; Karen J Fritchie
Journal:  J Clin Pathol       Date:  2014-11-05       Impact factor: 3.411

10.  Reduction of fibroblast size/mechanical force down-regulates TGF-β type II receptor: implications for human skin aging.

Authors:  Gary J Fisher; Yuan Shao; Tianyuan He; Zhaoping Qin; Daniel Perry; John J Voorhees; Taihao Quan
Journal:  Aging Cell       Date:  2015-10-08       Impact factor: 9.304

View more
  11 in total

Review 1.  Update on selected advances in the immunohistochemical and molecular genetic analysis of soft tissue tumors.

Authors:  Khin Thway; Andrew L Folpe
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

Review 2.  How Technology Is Improving the Multidisciplinary Care of Sarcoma.

Authors:  Inga-Marie Schaefer; Kelvin Hong; Anusha Kalbasi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

3.  PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm.

Authors:  Maribel D Lacambra; Ilan Weinreb; Elizabeth G Demicco; Chit Chow; Yun-Shao Sung; David Swanson; Ka-Fai To; Kwok-Chuen Wong; Cristina R Antonescu; Brendan C Dickson
Journal:  Genes Chromosomes Cancer       Date:  2019-04-30       Impact factor: 5.006

Review 4.  WHO Pathology: Highlights of the 2020 Sarcoma Update.

Authors:  Inga-Marie Schaefer; Alessandro Gronchi
Journal:  Surg Oncol Clin N Am       Date:  2022-05-31       Impact factor: 2.402

5.  A novel EWSR1-HOXB13 rearrangement in a fibroblastic tumor from the abdomen of a young woman.

Authors:  Harumi Nakamura; Yoji Kukita; Hironari Tamiya; Satoshi Takenaka; Toshinari Yagi
Journal:  Virchows Arch       Date:  2022-01-24       Impact factor: 4.535

6.  Ewing sarcoma and related FET family translocation-associated round cell tumors: A century of clinical and scientific progress.

Authors:  Robert G Maki; Patrick J Grohar; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2022-04-30       Impact factor: 4.263

7.  NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects.

Authors:  Vasiliki Siozopoulou; Elly Marcq; Koen De Winne; Koen Norga; Gertjan Schmitz; Valerie Duwel; Philippe Delvenne; Evelien Smits; Patrick Pauwels
Journal:  Pathol Oncol Res       Date:  2022-05-11       Impact factor: 2.874

Review 8.  New advances in the molecular classification of pediatric mesenchymal tumors.

Authors:  Albert J H Suurmeijer; Yu-Chien Kao; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2018-10-11       Impact factor: 5.006

Review 9.  What's new in fibroblastic tumors?

Authors:  Susan M Armstrong; Elizabeth G Demicco
Journal:  Virchows Arch       Date:  2019-12-11       Impact factor: 4.064

10.  Sarcoma and the 100,000 Genomes Project: our experience and changes to practice.

Authors:  Sophie C Prendergast; Anna-Christina Strobl; William Cross; Nischalan Pillay; Sandra J Strauss; Hongtao Ye; Daniel Lindsay; Roberto Tirabosco; Jane Chalker; Shazia S Mahamdallie; Alona Sosinsky; Adrienne M Flanagan; Fernanda Amary
Journal:  J Pathol Clin Res       Date:  2020-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.